A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy agent (tisagenlecleusel) by the FDA in 2017. Between 2015 and 2019, the number of industry-sponsored genetic therapy trials more than quadrupled (CAGR + 43%), with the Asia-Pacific region being involved in about 40% of all trials (ex-Japan). Since 2001, over 300 sites in Asia-Pacific have been involved in 335 different genetic therapy trials.
노보텍, BIO 2023 APAC Summit 행사 및 바이오테크 분야에서 중국과의 관계 구축에 관한 Endpoints 패널 후원
미국, 매사추세츠주 보스턴 - 아시아 태평양 중심의 선도적인 바이오텍CRO인 노보텍은 BIO 202Read more